CD14+/S100A9+ MDSCs expanded in NSCLC patients and suppressed T cell proliferation via iNOS, ARG1, IL-10 and the IL-13/IL-4Rα pathway [32]. Here, S100A9 is linked to non-small cell lung carcinoma.